External Beam Radiation Therapy (EBRT)
Treatment for Hodgkin Lymphoma
Typical Dosage: 20-36 Gy in 10-20 fractions
Effectiveness
80%
Safety Score
25%
Clinical Trials
13
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
20-36 Gy in 10-20 fractions
Time to Effect
During/shortly after treatment
Treatment Duration
2-4 weeks
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$5,000
Side Effect Mgmt:$2,500
Total Annual:$42,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$47,222
Cost per Remission
$50,000
External Beam Radiation Therapy (EBRT) Outcomes
for Hodgkin Lymphoma
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Fatigue
+60%
Skin Irritation
+70%
Dysphagia (neck RT)
+40%
Pneumonitis (chest RT)
+7%
Hypothyroidism (neck RT, long-term)
+25%
Active Clinical Trials
6 active trials recruiting for External Beam Radiation Therapy (EBRT) in Hodgkin Lymphoma
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
NCT02494700ACTIVE NOT RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Houston, United States
Started: Jul 6, 2015
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05967416RECRUITINGPHASE1
24 participants
INTERVENTIONAL
Duarte, United States +2 more
Started: Jan 17, 2024
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
NCT07528352RECRUITINGPHASE1
12 participants
INTERVENTIONAL
Salt Lake City, United States
Started: Jun 1, 2026
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
NCT05800405RECRUITINGEARLY_PHASE1
9 participants
INTERVENTIONAL
Duarte, United States
Started: Jul 20, 2023
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT07572123NOT YET RECRUITINGPHASE2, PHASE3
374 participants
INTERVENTIONAL
Started: Dec 4, 2026
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399RECRUITINGPHASE2
461 participants
INTERVENTIONAL
Birmingham, United States +226 more
Started: Dec 17, 2020
Completed Clinical Trials
5 completed trials for External Beam Radiation Therapy (EBRT) in Hodgkin Lymphoma
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03210662COMPLETEDPHASE2
17 participants
INTERVENTIONAL
Houston, United States
Started: Feb 1, 2018
Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
NCT00188929COMPLETEDPHASE2
10 participants
INTERVENTIONAL
Toronto, Canada
Started: Aug 1, 2005
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
NCT03610061COMPLETEDPHASE1
34 participants
INTERVENTIONAL
Brisbane, Australia +2 more
Started: Nov 1, 2018
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592COMPLETEDPHASE2
159 participants
INTERVENTIONAL
Anchorage, United States +239 more
Started: Sep 1, 2011
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
NCT01678352COMPLETEDEARLY_PHASE1
19 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Oct 1, 2012